NVX-CoV2373 Nanoparticle Vaccine Effective Against COVID-19 B.1.351 Variant
A phase 2a-b study was conducted in South Africa to assess the safety and efficacy of the NVX-CoV2373 vaccine.
A phase 2a-b study was conducted in South Africa to assess the safety and efficacy of the NVX-CoV2373 vaccine.
The TeenCOVE study (ClinicalTrials.gov: NCT04649151) included over 3700 US adolescents aged 12 to less than 18 years.
The FDA has authorized undiluted, thawed vials of the Pfizer-BioNTech COVID-19 Vaccine to be stored in the refrigerator at 2°C to 8°C (35°F to 46°F) for up to 1 month.